OBJECTIVE
Presenting a poor prognosis, gastric cancer (GC) remains one of the leading causes of disease and death worldwide. N7-methylguanosine (m7G) is the most prevalent RNA modification. m7G-long noncoding RNAs (lncRNAs) regulate GC onset and progression, but their precise mechanism in GC is unclear.
MATERIALS AND METHODS
The Cancer Genome Atlas database helped extract gene expression data and clinical information for GC. Coexpression analysis helped identify m7G-related lncRNAs. Univariate Cox and multivariate Cox analyses helped identify m7G-related lncRNAs with predictive capability. The chi square test was used to study the relationship between the expression of lncRNAs and clinical characteristics. Enrichment analysis (GSEA) was used for pathway enrichment analysis.
RESULTS
Thirty-one m7G lncRNAs were identified by coexpression analysis. Further univariate Cox and multivariate Cox analyses were used to screen the prognostic lncRNAs. There is only one lncRNA, REPIN1 antisense RNA 1 (REPIN1-AS1), that can be used as an independent prognostic factor. Therefore, REPIN1-AS1 was selected as the molecule for further study. Then, REPIN1-AS1 was enriched by GSEA. Finally, drug sensitivity was analysed.
CONCLUSIONS
We constructed a m7G-related lncRNA prognostic model, and the results showed that REPIN1-AS1 could be an independent prognostic factor involved in tumour formation and other signalling pathways and had potential therapeutic targets.